hotspot -WSS

hotspot

author：focus 2025-09-28 02:47:53 - browse：63276

A display of TVs against an orange background. -- health policy coverage from STAT — Adobe

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a regulation that’s been 13 years in the making.

White House budget experts are reviewing changes to the regulation of broadcast drug advertisements that the Food and Drug Administration proposed in 2010, according to the Office of Management and Budget website. That proposal aimed to make commercials present drug risks in a manner that consumers notice and understand.

Drug ads have long been controversial. Aside from New Zealand, the United States is the only country that allows drug makers to advertise to consumers. Critics of drug ads say they pose consumer safety concerns by bombarding the public with promotions that distract viewers from potential side effects. Drug companies say commercials spark conversations between patients and doctors that promote clinically beneficial prescribing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Telehealth for opioid use disorder is lifesaving

entertainment

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Readout Newsletter: Biotech news today

Hospitals consider fixing cancer drug shortages on their own

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Diverse clinical trials: Why aren’t we there yet?

explore

hotspot

entertainment

At least 13 dead in Texas as scorching temps continue

FDA approves updated Covid vaccines

United colonoscopy coverage change 'may cost lives,' doctors say

Will the IRA bring competition to the biologics market?

Novavax promises a turnaround & Lilly roils the obesity market

Smaller biotechs seek to piggyback on weight loss drug boom

23andMe had bad news about my health. I wish a person had delivered it

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

How one medical school became remarkably diverse

FDA panel endorses Alnylam’s heart drug — after picking it apart

focus

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

J&J lung cancer data amount to new salvo against AstraZeneca

ADCs take center stage as promising cancer treatments

PEPFAR is under serious threat — and so is global health

New weight loss drugs vying to be the next Wegovy or Mounjaro

focus

entertainment

entertainment

hotspot